Learn More
BACKGROUND To reduce side-effects of corticosteroid-containing antiemetic regimens, tailoring antiemetic schedules to specific requirements of different patients could be of benefit. We evaluated the(More)
8506 Background: High dose IFNalfa2b, according to the ECOG 1684 schedule, is the only approved adjuvant treatment for stage III melanoma. The risk/benefit profile has limited its use, while efficacy(More)
PURPOSE To determine the feasibility of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by concurrent chemoradiotherapy (CHT-RT) compared with the same CHT-RT regimen alone in(More)